CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

201281Orig1s000

Trade Name: JENTADUETO

Generic Name: linagliptin and metformin hydrochloride

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.

Approval Date: January 30, 2012

Indications: a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

CENTER FOR DRUG EVALUATION AND RESEARCH

201281Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	**X**
Labeling	**X**
REMS	
Summary Review	**X**
Officer/Employee List	**X**
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	**X**
Chemistry Review(s)	**X**
Environmental Assessment	**X**
Pharmacology Review(s)	**X**
Statistical Review(s)	**X**
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	**X**
Other Reviews	**X**
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	**X**
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

201281Orig1s000

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 201281

NDA APPROVAL

Boehringer Ingelheim Pharmaceuticals, Inc.
Attention: Dawn Collette
Associate Director, Drug Regulatory Affairs
900 Ridgebury Rd/ P.O. Box 368
Ridgefield, CT 06877-0368

Dear Ms. Collette:

Please refer to your New Drug Application (NDA) dated and received January 19, 2011, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, for linagliptin and metformin tablets (2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg).

We acknowledge receipt of your amendments dated January 28, March 11, April 12, 19 and 27, May 19, June 1 and 13, July 1 and 27, August 3, 17 and 26, September 1, 15 and 21, November 1 (2), 3, 7, 8 and 30, 2011, and January 17, 2012. The November 30, 2011, submission constituted a complete response to our action letter dated November 16, 2011. We also acknowledge receipt of your email dated January 27, 2012, that includes the agreed-upon labeling.

This new drug application provides for the use of Jentadueto (linagliptin and metformin fixed-dose combination) tablets as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and the patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels submitted on November 8, 2011, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled "Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)." Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 201281**". Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

We remind you of your requirements under the Pediatric Research Equity Act (PREA) as stated in the approval letter for NDA 201280 for Tradjenta (linagliptin), dated May 2, 2011:

PMR 1766-1: A randomized, placebo-controlled, dose-finding study under PREA evaluating at least two doses of linagliptin as monotherapy in pediatric patients ages 10 to 16 years (inclusive).

Final Protocol Submission: by November 30, 2011
Trial Completion: by February 28, 2014
Final Report Submission: by August 31, 2014

PMR 1766-2: Deferred randomized and controlled pediatric study under PREA to evaluate efficacy, safety, and pharmacokinetics of linagliptin for the treatment of type 2 diabetes mellitus in pediatric patients ages 10 to 16 years (inclusive) as monotherapy and when added to metformin therapy.

Final Protocol Submission: by June 30, 2014
Trial Completion: by March 31, 2017
Final Report Submission: by September 30, 2017

Please cross-reference this NDA when you submit your final study reports.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Mehreen Hai, Ph.D., Regulatory Project Manager, at (301) 796-5073.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:

Package Insert
Patient Package Insert
Professional sample label 2.5 mg/500 mg - 14 tablets
Trade bottle label 2.5 mg/500 mg - 60 tablets
Trade bottle label 2.5 mg/500 mg - 180 tablets
Trade bottle label 2.5 mg/500 mg - 2000 tablets
Professional sample label 2.5 mg/850 mg - 14 tablets
Trade bottle label 2.5 mg/850 mg - 60 tablets
Trade bottle label 2.5 mg/850 mg - 180 tablets
Trade bottle label 2.5 mg/850 mg - 2000 tablets
Professional sample label 2.5 mg/1000 mg - 14 tablets
Trade bottle label 2.5 mg/1000 mg - 60 tablets
Trade bottle label 2.5 mg/1000 mg - 180 tablets
Trade bottle label 2.5 mg/1000 mg - 2000 tablets

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY H PARKS
01/30/2012